Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 384

1.

Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.

Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S.

Am J Hematol. 2013 Apr;88(4):251-60. doi: 10.1002/ajh.23386. Epub 2013 Mar 5.

2.
3.

Deferasirox for managing iron overload in people with thalassaemia.

Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.

Cochrane Database Syst Rev. 2017 Aug 15;8:CD007476. doi: 10.1002/14651858.CD007476.pub3. Review.

PMID:
28809446
4.

The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.

ElAlfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A.

J Pediatr Hematol Oncol. 2010 Nov;32(8):601-5. doi: 10.1097/MPH.0b013e3181ec0f13. Erratum in: J Pediatr Hematol Oncol. 2011 Oct;33(7):572. El Alfy, Moshen [corrected to ElAlfy, Moshen S].

PMID:
20921906
5.

The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.

Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.

Pediatr Blood Cancer. 2015 Sep;62(9):1592-6. doi: 10.1002/pbc.25533. Epub 2015 Mar 28.

PMID:
25820920
6.

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A.

Eur J Haematol. 2009 Jun;82(6):458-65. doi: 10.1111/j.1600-0609.2009.01228.x. Epub 2009 Jan 28.

7.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
8.

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.

Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.

Eur J Haematol. 2001 Jul;67(1):30-4.

PMID:
11553264
9.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.

Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Review.

PMID:
23963793
10.

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.

Calvaruso G, Vitrano A, Di Maggio R, Lai E, Colletta G, Quota A, Gerardi C, Rigoli LC, Sacco M, Pitrolo L, Maggio A.

Am J Hematol. 2015 Jul;90(7):634-8. doi: 10.1002/ajh.24024. Epub 2015 May 3.

11.

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.

Ann Hematol. 2008 Jul;87(7):545-50. doi: 10.1007/s00277-008-0471-2. Epub 2008 Mar 20.

PMID:
18351337
12.

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.

Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.

Eur J Haematol. 2015 Nov;95(5):411-20. doi: 10.1111/ejh.12507. Epub 2015 Mar 27.

PMID:
25600572
13.

A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.

Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.

Hemoglobin. 2006;30(2):263-74.

PMID:
16798652
14.

A trial of deferiprone in transfusion-dependent iron overloaded children.

Lucas GN, Perera BJ, Fonseka EA, De Silva DD, Fernandopulle M.

Ceylon Med J. 2000 Jun;45(2):71-4.

PMID:
11051705
15.
16.

[Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].

Gao HY, Li Q, Chen JJ, Chen GF, Li CG.

Zhongguo Dang Dai Er Ke Za Zhi. 2011 Jul;13(7):531-4. Chinese.

17.

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.

Circulation. 2007 Apr 10;115(14):1876-84. Epub 2007 Mar 19.

18.

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F.

Blood. 2003 Sep 1;102(5):1583-7. Epub 2003 May 22.

19.

Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.

Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.

Pediatr Hematol Oncol. 2014 Feb;31(1):76-86. doi: 10.3109/08880018.2013.861046. Epub 2014 Jan 2.

PMID:
24383712
20.

A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.

Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.

Hemoglobin. 2009;33(5):323-31. doi: 10.3109/03630260903211979.

PMID:
19814678

Supplemental Content

Support Center